Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Executive Summary
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
You may also be interested in...
FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.